The body thinks its in danger and prepares to flee
The peptide was first extracted from calf thymus in the 1970s and in the decades since has been subject to a number of studies including human clinical trials
Regulatory scrutiny of advertising practices may support broader arguments that marketing outpaced the science
Unlike GLP-1, supraphysiologic GIP infusions do not amplify the late phase insulin response to glucose in patients with T2DM ( Native GLP-1 and GIP have limited pharmacologic value because of their short plasma half-life (17 min) ( Leveraging the Incretin Effect for the Treatment of T2DM Because of the apparent lack of beta-cell responsiveness to GIP in patients with poorly controlled T2DM, most therapeutic strategies have focused on enhancing the activity of GLP-1
Biological Activity 50 & Target EC50: 5 nM (GLP-1 receptor) [2] In Vitro TT-OAD2 (0-10 M) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and -arrestin responses in a concentration-dependent manner in HEK293A cells [1]
Protocols, vials, and the reconstitution calculator The Protocol card on the Doses tab is your whole regimen at a glance: each compound with its dose, schedule, and cycle status